Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6126971	UPJOHN	Stable oral CI-981 formulation and process for preparing same	Jan, 2013 (11 years ago)
US6126971 (Pediatric)	UPJOHN	Stable oral CI-981 formulation and process for preparing same	Jul, 2013 (10 years ago)
US5686104	UPJOHN	Stable oral CI-981 formulation and process of preparing same	Nov, 2014 (9 years ago)
US5686104 (Pediatric)	UPJOHN	Stable oral CI-981 formulation and process of preparing same	May, 2015 (8 years ago)
US5969156	UPJOHN	Crystalline [R- (R,R)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)	Jul, 2016 (7 years ago)
US5969156 (Pediatric)	UPJOHN	Crystalline [R- (R,R)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)	Jan, 2017 (7 years ago)

Lipitor is owned by Upjohn.

Lipitor contains Atorvastatin Calcium.

Lipitor has a total of 6 drug patents out of which 6 drug patents have expired.

Expired drug patents of Lipitor are:

Lipitor was authorised for market use on 17 December, 1996.

Lipitor is available in tablet;oral dosage forms.

Lipitor can be used as method of inhibiting cholesterol biosynthesis and treating hypercholesterolemia and method for treating hyperlipidemia.

The generics of Lipitor are possible to be released after 23 June, 2020.

Drug Exclusivity	Drug Exclusivity Expiration
M(M-204)	Jun 23, 2020

Market Authorisation Date: 17 December, 1996

Treatment: Method of inhibiting cholesterol biosynthesis and treating hypercholesterolemia and method for treating hyperlipidemia

Dosage: TABLET;ORAL

Lipitor patents expiration